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Renal dysfunction seen in patients with American cutaneous
leishmaniasis (ACL) has been attributed to the use of
antimonials for treatment. To determine whether ACL itself
causes tubular dysfunction, we measured renal function in
37 patients with ACL prior to their treatment and compared
results to that in 10 healthy volunteers of similar mean age.
None of the patients presented with glomerular dysfunction;
however, 27 had a urinary concentrating defect. There was
no statistical difference between groups in the pre- and
post-desmopressin test of urine osmolality, but the post-test
urine osmolality of the controls was significantly higher.
Urinary AQP2 levels, determined by western blot of isolated
exosomes, were found to be significantly lower in patients
than in controls, whereas that of the cotransporter (NKCC2)
was significantly higher. A urinary acidification defect (post-
test pH greater than 5.50 following calcium chloride) was
found in 15 patients. Pretest plasma bicarbonate was below
normal in 12 patients as was the pretest plasma pH in 14.
Expression of the Na/H exchanger (NHE3), Hþ -ATPase, and
pendrin were all significantly higher in patients with ACL
than in controls. A combined urinary concentration and
acidification defect was found in
12 patients. Thus, the urinary concentrating defect of ACL
may be caused by decreased AQP2, with increased NKCC2
compensatory. Pendrin upregulation may be related to the
urinary acidification defect with increased NHE3 and
Hþ -ATPase also compensatory. Hence, ACL can cause
asymptomatic renal tubular dysfunction.
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Leishmaniasis is an infectious, non-contagious, zoonotic
disease caused by intra-macrophage protozoa of the genus
Leishmania, which are transmitted by a vector belonging to
the family Psychodidae.1 The disease has a wide geographical
distribution, occurring on nearly every continent. It is
endemic in tropical and subtropical regions, such as North-
east Africa and the Middle East, as well as parts of Europe,
Central America, and South America.2
There are three clinical types of leishmaniasis: visceral
(kala-azar), cutaneous, and mucosal. The parasite proliferates
into the mononuclear phagocytic system, dermis, and
nasopharyngeal mucosa, respectively.1
The cutaneous form is known as American cutaneous
leishmaniasis (ACL). Eight countries account for B90% of
all cases of ACL: Afghanistan, Pakistan, Syria, Saudi Arabia,
Nigeria, Iran, Brazil, and Peru.3 Traditionally, ACL has
been classified as Old-World leishmaniasis (species found in
the Mediterranean region, the Middle East, and Africa) or
New-World leishmaniasis (species found in Mexico, Central
America, and South America), the virulence, pathogeni-
city, and clinical manifestations depending on the species
involved.4
Studies of visceral leishmaniasis (VL) have demonstrated
renal involvement ranging from nonspecific abnormalities
on urinalysis to various types of glomerulonephritis.5–8 In
animal and human studies of VL, acute kidney injury (AKI)
has been attributed to a number of mechanisms: interstitial
nephritis secondary to the deposition of parasite antigens in
the renal interstitium;9 hypersensitivity to antimonials;10,11
and deposition of immune complexes, leading to rapidly
progressive glomerulonephritis.12 In the presence of leishman-
iasis, AKI increases mortality.13 Renal tubular dysfunction
has also been described in VL, manifesting as urinary
concentrating defect, with or without urinary acidification
defect. In a prospective study of 50 patients with VL, urinary
concentrating defect was found in 68%, urinary acidifica-
tion defect was found in 64%, and complete renal tubular
acidosis was found in 30%.14 Another prospective study of
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VL patients demonstrated proximal tubular dysfunction, as
determined by urinary levels of retinol-binding protein, in
nearly half of the patients.6
In the literature, there are very few data regarding renal
dysfunction in ACL, and the renal abnormalities described
have been associated with the use of pentavalent anti-
monials.10 Patients with ACL can develop AKI due to massive
deposition of immune complexes that appear after the
destruction of the parasites (Leishman–Donovan bodies), a
phenomenon similar to the Herxheimer reaction.15 Sampaio
et al.,16 in a prospective study of 11 patients with ACL, who
received a high daily dose of an antimonial (40mg/kg body
weight (BW)) for 30 days, observed one case of AKI.16
The authors found that, after 30 days of treatment, eight
patients showed a reduction in the glomerular filtration rate
(GFR), accompanied by tubular dysfunction, together with
a reduction in urinary concentrating ability and an increase
in the fractional excretion of sodium.16
When administered at low doses and for a short period,
antimonials have low renal toxicity. However, in the treat-
ment of ACL, it is often necessary to use higher doses for a
longer period, which can increase toxicity. There are also
reports of proteinuria and AKI in patients with ACL.10,16–18
In an experimental animal study,19 high doses of an anti-
monial were shown to result in impaired urinary concentrat-
ing ability without a reduction in GFR. This abnormality was
attributed to inhibition of antidiuretic hormone secretion
and to a direct effect of the drug on tubular cells. In some
animals, high doses of the antimonial also caused a reduction
in the GFR.19
To determine whether ACL itself causes tubular dysfunc-
tion, we studied the renal function of 37 ACL patients before
antimonial treatment.
RESULTS
All of the 59 patients recruited had previously been diagnosed
with ACL on the basis of epidemiological, clinical, biochem-
ical, and histopathological findings. Of those 59 patients,
22 were excluded: eight for testing negative on a new histo-
pathological exam; nine for being under 15 years of age
or over 60 years of age; two for subsequently declining
to participate in the study; one for having hypertension;
one for having diabetes mellitus; and one for having used
an antimonial (meglumine antimoniate) within the last
30 days. Therefore, the study group comprised 37 ACL
patients.
The mean age was 35.6±12 years in the study group and
32.2±11.7 years in the control group. In the study group,
19 (51.4%) were male. Twenty-two (59.5%) of the patients
tested positive on the Montenegro skin test. All 37 patients
had isolated skin lesions: 27 had only one lesion; 7 had two to
four lesions; and 3 had more than four lesions. The mean
duration of disease was 28.5±20.6 days (range, 7–90 days).
Demographic and clinical data are shown in Table 1.
In comparison with the controls, none of the patients
had significant glomerular dysfunction (109.6±32 vs
116.3±23ml/min per 1.73m2, P¼ 0.694). None of the
patients presented a GFR of o60ml/min.
Tubular defects
Post-desmopressin test urinary concentrating ability was
lower in ACL patients than in controls. Urinary concentrating
defect, defined as a urine osmolality (Uosm)/plasma osmo-
lality (Posm) ratio o2.8, was observed in 27 patients (77%).
Although pre- and post-desmopressin test values of Uosm
were comparable in the study group, Uosm was significantly
lower in the patients than in the controls (618±202 vs
985±81, Po0.05).
Urinary acidification defect, defined as the inability to
reduce urinary pH (UpH) to o5.50 after CaCl2 administra-
tion, was observed in 15 patients (40.5%). Although there
was no significant difference between patients and controls
in terms of the mean plasma bicarbonate concentration,
the pre-CaCl2 plasma bicarbonate concentration was
o22mEq/l in 12 of the 15 patients with urinary acidifica-
tion defect.
Combined urinary concentration and acidification defect
was observed in 12 patients. Only five patients had no
defect in urinary concentration or acidification. Figure 1a
and b illustrate Uosm and UpH before and after the test with
desmopressin and CaCl2 in the ACL patients.
Comparing the patients who presented tubular (concen-
tration or acidification) defects with the remaining patients,
we found no differences in relation to age, gender, duration
of disease, number of skin lesions, Montenegro skin test
positivity, or body mass index. We detected no abnormali-
ties in relation to plasma concentrations or fractional
excretions of sodium, potassium, calcium, or phosphorus.
Comparing the ACL patients with the controls, we found that
Table 1 | Demographic and clinical characteristics, by group
Characteristic
ACL
(n=37)
Control
(n=10) P a
Age (years), mean±s.d. 35.6±12 32.3±11.7 0.442
Gender, n (%)
Male 19 (51.4) 6 (60) 0.73
Female 18 (48.6) 4 (40)
Duration of disease (days),
mean±s.d.
28.5±20.6 — —
Montenegro skin test (±), n 22/37 — —
Number of skin lesions, n (%)
1 27 (72.9) — —
2–4 7 (18.9) — —
44 3 (8.1) — —
Systolic blood pressure (mmHg),
mean±s.d.
122±10 117±9.5 0.221
Diastolic blood pressure (mmHg),
mean±s.d.
80±4.7 75±8.5 0.079
Abbreviation: ACL, American cutaneous leishmaniasis.
aStudent’s t-test.
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the former showed higher urinary fractional excretion of
calcium, potassium, and magnesium (Table 2). However, we
found no difference between the groups in terms of
serum electrolyte levels. It is noteworthy that plasma
magnesium levels differed only between the patients with
urinary acidification defect and those without (2.15±0.06 vs
2.33±0.04, P¼ 0.02).
Microalbuminuria, defined as an albumin/creatinine ratio
430mg/g, was detected in 12 (35.3%) of 34 patients tested
(Table 2). Two patients had microalbuminuria alone, nine
had microalbuminuria and urinary concentration defect,
and another had urinary acidification defect alone. None
of the patients with urinary acidification defect and
urinary concentration defect had an albumin/creatinine
ratio 430mg/g.
Urinary exosomes
As can be seen in Figure 2a, urinary protein expression of
the collecting duct water channel aquaporin 2 (AQP2)
was significantly lower in the patients than in the controls
(38.5±12 vs 99.5±0.5%, P¼ 0.006). Figure 2b shows
that the expression of Na-K-2Cl cotransporter (NKCC2)
was significantly higher in the patients than in the
controls (147±12 vs 102±2.5%, P¼ 0.02). In addition,
Figures 3, 4a and b show that urinary protein expres-
sion of the Na/H exchanger (NHE3), Hþ -ATPase, and
pendrin, respectively, was significantly higher in the
patients than in the controls (176±15 vs 100±0.6%,
P¼ 0.015; 190±8 vs 98±0.2%, P¼ 0.04; and 176±15 vs
100±0.6%, P¼ 0.015).
DISCUSSION
Here, we have demonstrated that ACL can cause tubular
dysfunction without a drop in GFR. Our findings also
indicate that, in patients with ACL, reduced expression of
AQP2 leads to impaired urine concentrating ability. In
addition, ACL patients showed a marked increase in the
urinary protein expression of NKCC2.
In this study, ACL was associated with dysregulation of
major acid–base transporters in the proximal tubule (NHE3)
and the distal nephron (Hþ -ATPase and pendrin). There-
fore, ACL can impair the ability of the kidneys to respond
appropriately to an acute acid load.
Although it has been shown that patients with VL develop
renal dysfunction,5–8 there are few data regarding such
dysfunction in patients with ACL. Studies of ACL have
attributed renal dysfunction to the use of pentavalent
antimonials.10 However, in this study, we showed that, before
antimonial treatment, patients with ACL had asymptomatic
renal tubular dysfunction, as evidenced by their inability to
concentrate and acidify urine, albeit without glomerular
dysfunction.
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Figure 1 |Urine concentration and acidification capacity in
ACL patients pre- and post-desmopressin test and pre- and
post-CaCl2 test. (a) Uosm pre- and post-desmopression test in ACL
patients with normal or abnormal urinary concentration. (b) UpH
pre- and post-CaCl2 test in ACL patients with normal or abnormal
urinary acidification. ACL, American cutaneous leishmaniasis; NS,
nonsignificant; Uosm, urine osmolality; UpH, urinary pH.
Table 2 | Renal function, by group
Variable
ACL (n=37),
mean±s.d.
Control (n=10),
mean±s.d.
Pcreat (mg/dl) 0.81±0.16 0.85±0.18
CrCl (ml/min per 1.73m2) 109.6±31.5 116.4±22.7
Post-DT U/Posm 2.19±0.73 3.47±0.33*
Post-CaCl2 UpH 5.45±0.64 4.82±0.20*
Post-DT Uosm (mOsm/kg
H2O)
618±202 965±81*
FENa (%) 1.15±0.74 0.73±0.39
FEK (%) 10±6.6 7.50±2.8*
FECa (%) 1.07±0.72 0.62±0.34*
FEP (%) 10.9±9.98 9.10±6.4
FEMg (%) 1.81±1.70 0.90±0.40*
Albumin/creatinine ratio
(mg/g)
23.6±26 6.12±4.06*
Abbreviations: ACL, American cutaneous leishmaniasis; CaCl2, calcium chloride test;
CrCl, creatinine clearance; DT, desmopressin test; FE, fractional excretion; Pcreat,
plasma creatinine; U/Posm, urinary/plasma osmolality ratio; Uosm, urinary osmolality;
UpH, urinary pH.
*Po0.05 (Student’s t-test; Mann–Whitney test).
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Because the development of ACL depends solely on the
level of exposure to the vector, it can occur at any age.1 The
mean age of the patients studied by Lima Verde et al.14 was
29±11 years, compared with 36±15 years for those studied
by Oliveira et al.13 The mean age of our study sample was
35.6±12 years. Therefore, patient age cannot be considered a
source of bias in this study.
Among our patients, the mean duration of disease was
28.5±20.6 days (range, 7–90 days), which is not character-
istic of chronic exposure to highly antigenic material. In a
previous retrospective study of 151 patients with ACL, 97.2%
tested positive on the Montenegro skin test, higher than the
59.0% observed in our study.20 In our study sample, 72.9% of
the patients had only one skin lesion, compared with 69.5%
in a study conducted by Schubach et al.20 In studies involving
only patients with localized disease, Montenegro skin test
positivity has been shown to be 82–89%.21,22 The test does
not distinguish recent infection from past infection, and its
importance in endemic areas is questionable.
Various studies of VL have reported glomerular involve-
ment. In a prospective study of 50 patients with VL, Lima
Verde et al.14 observed that 14 (28%) had a reduction in GFR
ofo80ml/min per 1.73m2. In another study of VL patients,
AKI was observed in 76 (33.9%) of the 224 patients
evaluated.13 Reports of glomerular dysfunction in ACL have
been associated with the use of pentavalent antimonials.10
Other infectious diseases that primarily affect the skin and
nerves, such as leprosy, can also lead to glomerular
dysfunction. In a prospective study of 59 patients with
leprosy, Oliveira et al.23 observed a reduction in GFR in 50%
of the cases. However, in our study sample, no significant
GFR abnormality was observed, suggesting that ACL, per se,
does not cause glomerular dysfunction.
There is considerable evidence that antimonial treatment
causes impaired urine concentrating ability in ACL. In a
study involving 11 ACL patients treated with meglumine
antimoniate at a daily dose of 40mg/kg BW (double dose) for
30 days, Sampaio et al.16 found that 8 of the patients had
impaired urine concentrating ability after 16 h of water
deprivation. Veiga et al.24 reported that five ACL patients
treated with a conventional dose, but for a longer period,
developed an inability to concentrate urine after treatment.24
Lima Verde et al.14 reported impaired post-desmopressin test
urine concentrating ability in 68% of the 50 VL patients
studied.14 In an experimental study with toad bladder, which
has a phylogenetic structure similar to the renal collecting
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Figure 2 |Western blotting analysis in the urinary exosome
fraction, normalized to urinary creatinine, in controls and
in patients with ACL. Abundance of (a) AQP2 and (b) NKCC2.
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tubule, it was demonstrated that antimonial administration
inhibits osmotic stimulated water flow.25 In an experimental
study with rats receiving the antimonial sodium stibogluco-
nate at a daily dose of 30mg/100 g for 30 days, there was
post-treatment tubular abnormality, without glomerular
dysfunction. However, when a dose of 200mg/100 g was
administered, there was significant glomerular dysfunction.19
Nevertheless, in our sample of ACL patients evaluated before
treatment, we demonstrated that Uosm was significantly
reduced, indicating that ACL, in and of itself, can impair
urine concentrating ability.
According to the literature on leishmaniasis, urinary
acidification defect is less common than is urinary concen-
trating defect. In a study of patients with VL treated with the
standard dose of meglumine antimoniate, 64% showed an
inability to reduce UpH to o5.50 after the CaCl2 test.19
Although the patients evaluated in this study had ACL rather
than VL, we identified an inability to acidify urine in 46%,
calling into question the role that antimonial treatment has
in the development of tubular dysfunction in leishmaniasis.
It has been demonstrated that, in patients with VL,
hypomagnesemia is accompanied by an increase in urinary
excretion of magnesium.26 In ACL patients, we demonstrated
an increase in the fractional excretion of magnesium.
However, we found that serum levels of magnesium were
depressed only in patients with urinary acidification defect.
We speculate that the tubular defects seen in VL are also
present in ACL, although they are probably less common in
the latter.
There have been few studies evaluating microalbuminuria
in leishmaniasis. In one study of patients with VL, 81.8%
presented microalbuminuria.6 In a study of patients with
multibacillary leprosy, Oliveira et al.23 identified microalbu-
minuria in 8.5%. In this study, microalbuminuria was
identified in 35% of the ACL patients evaluated. Micro-
albuminuria is a widely accepted marker of incipient diabetic
nephropathy. However, further studies are needed in order to
determine the importance of microalbuminuria for the early
detection of glomerular dysfunction in infectious diseases. Of
the 15 patients with urinary acidification defect, only 1 had
microalbuminuria, suggesting a separate process.
Exosomes containing vesicular membranes and intracel-
lular fluid are normally secreted into the urine from all
nephron segments. Those exosomes contain proteins that can
be altered, in terms of their abundance or physical properties,
as a consequence of various renal diseases. A number of
studies have demonstrated that AQP2 is excreted in urine
through small membranous vesicles and that its abundance
in the urine is correlated with its expression in renal
tissue.27–29 After the discovery of AQP2, other urinary
transporters were identified and came to be used in the
study of tubular dysfunction.30 It has been demonstrated that
most membrane transporters are naturally expressed as high-
molecular-weight complexes and can be identified in urine.31
The collection and analysis of urine samples is an ideal non-
invasive means of evaluating biomarkers for the diagnosis of
renal diseases, because urine contains exosomes with
membrane and intracellular proteins from all segments of
the nephron.32,33 Among the relevant transporters are AQP2,
NHE3, NKCC2, Hþ -ATPase, and pendrin.34 In this study, a
high percentage of the patients had urinary concentrating
defect, as evidenced by reduced urinary expression of AQP2.
This was accompanied by increased expression of NKCC2,
which could represent a compensatory mechanism. Located
in the proximal tubule, the NHE3 isoform is the principal
agent of bicarbonate generation and reabsorption. One-third
of the renal cortical collecting duct cell population comprises
intercalated cells, which are ultimately responsible for
regulating the acid–base balance.35 In response to acid or
alkali loading, cortical collecting duct cells reabsorb or secrete
more bicarbonate, respectively. This is accomplished through
the coordinated activity of two types of intercalated cells:
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a-intercalated cells, which are able to secrete acid through an
apical Hþ -ATPase and basolateral Cl/HCO3
 exchanger; and
b-intercalated cells, which are able to secrete bicarbonate
through an apical Cl/HCO3
 exchanger and a basolateral
Hþ -ATPase. Pendrin is an apical Cl/HCO3
 exchanger in
b-intercalated cortical collecting duct cells. It has been shown
that metabolic acidosis decreases the activity of the apical
pendrin in b-intercalated cells of the rat cortical collecting
duct by reducing the overall expression of pendrin.36,37
Mohebbi et al.38 showed that protein expression of pendrin
increases during NH4CL loading in FK506 rats, altering the
expected renal response to acidosis. In this study, we
demonstrated that urinary expression of pendrin is increased
in the urinary exosomes of patients with ACL. The increase in
pendrin expression might be the key mechanism of urinary
acidification defect. However, we cannot explain why the
expression of this protein is increased in ACL. Further studies,
in humans and in animal models, are warranted in order to
confirm this hypothesis. We also found that there was an
increase in NHE3 and Hþ -ATPase expression in urinary
exosomes. It is possible that the marked increase in NHE3
and Hþ -ATPase expression presented by the ACL patients
represents a compensatory response to the increase in pendrin
expression and consequently to the urinary acidification
defect. However, we cannot rule out the possibility that other
transporters are involved in ACL-related metabolic acidosis.
We can conclude that ACL can cause asymptomatic renal
tubular dysfunction, manifesting as the inability to concen-
trate and acidify urine, without impairing glomerular
filtration. The analysis of urinary transporters was useful
in the detection of dysfunction at the molecular level. Further
studies, involving larger patient samples and including
other infectious diseases, are needed in order to confirm
our findings.
MATERIALS AND METHODS
Participants
This was a prospective study of 37 patients with a confirmed
diagnosis of ACL (based on epidemiologic, clinical, and biochemical
findings), recruited from among those treated between July 2008
and July 2009 at a public health facility in the city of Barbalha,
Brazil. The following exclusion criteria were applied: being under
15 years of age or over 60 years of age; having used pentavalent
antimonials within the last 30 days; presenting with hypertension
(systolic blood pressure X140mmHg or diastolic blood pressure
X90mmHg); having diabetes mellitus; having a urinary tract
infection; having systemic lupus erythematosus or another colla-
genosis; and having a history of renal disease. All patients were
scheduled to undergo standard treatment with the antimonial
meglumine antimoniate (Glucantime) at a daily dose of 20mg/kg of
BW for 20 days. All tests were conducted before the initiation of the
treatment. We also recruited a group of 10 healthy volunteers to be
evaluated as controls.
The study protocol was approved by the Research Ethics
Committee of the Federal University of Ceara´ School of Medicine
Walter Cantı´dio University Hospital, located in the city of Fortaleza,
Brazil. All participants gave written informed consent.
Diagnosis
The diagnosis of ACL was confirmed on the basis of epidemiological
and clinical criteria, as well as on the results of the Montenegro skin
test and the identification of parasites in a tissue biopsy.
Clinical and biochemical characteristics
At the time of the medical consultation, all symptoms and signs
were evaluated. We also collected data related to race, age, gender,
history of chronic diseases, number of skin lesions, duration of
disease, use of drugs, body mass index, blood pressure, Montenegro
skin test results, and ACL classification. The following laboratory
tests were conducted in blood or plasma: urea, creatinine, pH,
bicarbonate, sodium, potassium, chloride, magnesium, calcium,
phosphorus, albumin/globulin, amylase, fasting glucose, and
erythrocyte sedimentation rate. In urine samples, we evaluated the
following: creatinine, urea, sodium, potassium, chloride, calcium,
phosphorus, magnesium, microalbuminuria, urinalysis results,
Uosm, and UpH.
Renal function
We estimated GFR using the Cockroft and Gault formula, defining
abnormal GFR as p90ml/min per 1.73m2. In an isolated urine
sample collected before the concentration and acidification tests,
sodium, potassium, chloride, and magnesium were measured, and
the albumin/creatinine ratio was determined.
All patients underwent food and water deprivation for 12 h. We
calculated fractional excretions (sodium, potassium, calcium,
phosphorus, and magnesium) using the standard formula. Micro-
albuminuria was normalized to urinary creatinine.
We measured Uosm before and 4 h after intranasal administration
of desmopressin acetate (20 mg/kg BW).39,40 Urinary concentrating
ability was evaluated by determining the urinary/plasma osmolality
ratio (U/Posm) after 12 h of water deprivation.
Urinary acidification was evaluated by measuring UpH before and
after oral administration of CaCl2 (2mEq/kg BW).
41 Urinary
acidification defect was defined as a post-test UpH45.50.
Analytical methods
Urea concentration was determined by colorimetric-enzymatic assay
(Labtest, Lagoa Santa, Brazil), and the results are expressed in mg/dl.
Plasma and urinary levels of creatinine were determined by
colorimetric (picric acid) assay (Labtest) and by the Bonsnes–-
Taussky method, respectively, and the results are expressed in mg/dl.
Plasma and urinary sodium and potassium were determined by
photometry with a flame photometer (B462; Micronal, Sa˜o Paulo,
Brazil), and the results are expressed in mEq/l. Albumin and
globulin were determined by bromocresol reaction (Labtest), and
the results are expressed in g/dl. Glucose was determined by the
colorimetric glucose oxidase method (Labtest), and the results are
expressed in mg/dl. Alkaline phosphatase was determined by the
modified Bowers and McComb (phosphatase kinetics) method
(Labtest), and the results are expressed in U/l. Amylase was
determined by the modified Caraway colorimetric method, and
the results are expressed in U/dl. We determined plasma pH and
bicarbonate (HCO3
) using a blood gas analyzer (Rapidlab 238;
Chiron Diagnostics, Bayer, Tarrytown, NJ), and the results for
bicarbonate are expressed in mEq/l. We determined UpH using
digital pH-metry (pG1000; Gehaka, Sa˜o Paulo, Brazil). Urinary
osmolality was determined in a vapor pressure osmometer (5100C;
Wescor, Logan, UT), and the results are expressed in mOsm/kg
H2O. Urinalysis (to determine glucose, urobilin, bilirubin, ketone,
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protein, nitrite, leukocytes, hemoglobin, pH, and density) was
performed with reagent strips (Inlab URI-TEST; Mettler-Toledo,
Giessen, Germany). Urothelial cells, leukocytes, erythrocytes, and
bacteria were identified in urinary sediment under light microscopy
(magnification,  400). Microalbuminuria was identified through
immunoturbidimetry with a commercial kit (Tina-quant; Roche,
Mannheim, Germany), and the results are expressed in mg of
albumin/g creatinine.
Exosome sample processing
Urine samples were collected from the subjects (patients, n¼ 10;
controls, n¼ 5) after overnight (12 h) water deprivation. The
samples were placed into sterile 50-ml plastic tubes and immediately
stored in liquid nitrogen.
The samples were taken out of cold storage and placed on ice. As
the samples thawed, protease inhibitors (protease inhibitor cocktail;
Sigma, St Louis, MO) were added at a concentration of 10 ml/ml of
urine and the samples were subjected to extensive vortexing. The
mixed sample was then centrifuged at 17,000 g for 15min at 4 1C to
remove whole cells, large membrane fragments, and other debris.
The supernatant was centrifuged at 200,000 g for 1 h at 4 1C to
obtain low-density membrane pellets. The pellets were suspended in
isolation solution (200mmol/l Mannitol, 80mmol/l HEPES, and
41mmol/l KOH, pH 7.5) with protease inhibitors. All of the urinary
protein samples were stored at 80 1C until use.42,43
Electrophoresis and immunoblotting
Samples of membrane fractions were run either on 12.5%
polyacrylamide minigels (for AQP2) or on 10% polyacrylamide
minigels (for NHE3, NKCC2, Hþ -ATPase, and pendrin). Loading
amounts for gel electrophoresis were adjusted to equalize urinary
creatinine concentration. After transfer by electroelution to
nitrocellulose membranes (PolyScreen, PVDF Transfer; Life Science
Products, Boston, MA), blots were blocked with 5% milk and 0.1%
Tween 20 in PBS (sodium chloride 8.7 g/l, dibasic phosphate
7.2mmol/l, and monobasic phosphate 2.8mmol/l) for 1 h. Blots
were then incubated with one of the following: anti-AQP2 antibody
(1:2000), NKCC2 antibody (0.12 mg/ml), NHE3 antibody (1:500),
Hþ -ATPase (1:500), or pendrin (1:1000). The labeling was
visualized with horseradish peroxidase-conjugated secondary
antibody via the enhanced chemiluminescence detection system
(Amersham Pharmacia Biotech, Piscataway, NJ). Bands correspond-
ing to protein expression of AQP2, NHE3, NKCC2, Hþ -ATPase,
and pendrin were quantified by densitometric analysis using Image
Master VDS (Pharmacia Biotech, Buckinghamshire, UK) and are
expressed as percentages of control.
Antibodies
We obtained the peptide-derived polyclonal antibodies specific to
AQP2, NKCC2, NHE3, and pendrin from Santa Cruz Biotechnology
(Santa Cruz, CA).
The peptide-derived polyclonal antibody specific to V1ATPase
B1 subunit was kindly supplied by Dr Søren Nielsen (Institute of
Anatomy, University of Aarhus, Denmark).
Statistical analysis
All quantitative data are expressed as mean±s.e.m. The normality
of data distribution to quantitative variables was evaluated by
Shapiro–Wilk test. Differences between two parameters were analyzed
either by paired t-test or by nonparametric methods (Mann–Whitney
test). Values of Po0.05 were considered statistically significant.
DISCLOSURE
All the authors declared no competing interests.
ACKNOWLEDGMENTS
Financial support for this study was provided by the Brazilian
Conselho Nacional de Desenvolvimento Cientı´fico e Tecnolo´gico
(CNPq, National Council for Scientific and Technological
Development). The desmopressin acetate was provided
by Ferring of Brazil.
REFERENCES
1. Herwaldt BL. Leishmaniasis. Lancet 1999; 354: 1191–1199.
2. Roberts LJ, Handeman E, Foote SJ. Science, medicine and the future
Leishmaniasis. Br Med J 2000; 321: 801–804.
3. Desjeux P. Leishmaniasis: current situation and new perspectives.
Comp Immunol Microbiol Infect Dis 2004; 27: 305–318.
4. David CV, Craft N. Cutaneous and mucocutaneous leishmaniasis.
Dermatologic Therapy 2009; 22: 491–502.
5. Dutra M, Martinelli M, de Carvalho EM et al. Renal involvement in visceral
leishmaniasis. Am J Kidney Dis 1985; 6: 22–27.
6. Salgado Filho N, Ferreira TM, Costa JM. Envolvimento da func¸a˜o renal em
pacientes com leishmaniose visceral (calazar). Rev Soc Bras Med Trop
2003; 36: 217–221.
7. Chaigne V, Knefati Y, Lafarge R et al. A patient with visceral leishmaniasis
and acute renal failure in necrotizing glomerulonephritis. Nephrologie
2004; 25: 179–183.
8. Duvic C, Nedelec G, Debord T et al. Important parasitic nephropathies:
update from recent literature. Nephrologie 1999; 20: 65–74.
9. Councilman WT. Acute interstitial nephritis. J Experiment Med 1988; 3:
393–420.
10. Cuce´ LC, Belda Jr W, Dias W. Nephrotoxicity to Glucantimes in the
treatment of leishmaniasis. Rev Inst Med Trop S Paulo 1990; 32: 249–251.
11. Duarte MI, Silva MR, Gotto H. Interstitial nephritis in human kala-azar.
Trans R Soc Trop Med Hyg 1983; 77: 531–537.
12. Caravaca F, Munoz A, Pizarro JL et al. Acute renal failure in visceral
leishmaniasis. Am J Nephrol 1991; 11: 350–352.
13. Oliveira MJ, Silva Ju´nior GB, Abreu KL et al. Risk factors for acute kidney
injury in visceral leishmaniasis. Am J Trop Med Hyg 2010; 82: 449–453.
14. Lima Verde EM, Lima Verde FA, Lima Verde FA et al. Evaluation of renal
function in human visceral leishmaniasis (kala-azar): a prospective study
on 50 patients from Brazil. J Nephrol 2007; 20: 432–438.
15. Rodrigues ML, Costa RS, Souza CS et al. Nephrotoxicity attributed to
meglumine antimoniate (Glucantime) in the treatment of generalized
cutaneous leishmaniasis. Rev Inst Med Trop S Paulo 1999; 41: 1–5.
16. Sampaio RN, Paula CD, Sampaio JH et al. Avaliac¸a˜o da toleraˆncia e
nefrotoxicidade do antimonial pentavalente administrado na dose de
40mg Sbv/kg/dia por 30 dias na forma cutaˆnea-mucosa de leishmaniose.
Rev Soc Bras Med Trop 1997; 30: 457–467.
17. Balsan M, Fenech F. Acute renal failure in visceral leishmaniasis treated
with sodium stibogluconate. Trans Royal Soc Trop Med Hyg 1992; 86:
515–516.
18. Sampaio RN, Veiga JPR, Limeira OM et al. Insuficieˆncia renal aguda em
leishmaniose tegumentar americana tratada com a associac¸a˜o de
glucantime e alopurinol. Anais Brasileiros de Dermatologia 1991; 66:
133–134.
19. Veiga JP, Khanan R, Rosa TT et al. Pentavalent antimonial nephrotoxicity
in the rat. Rev Inst Med Trop Sa˜o Paulo 1990; 32: 304–309.
20. Schubach AO, Marzochi KB, Moreira JS et al. Retrospective study of 151
patients with cutaneous leishmaniasis treated with meglumine
antimoniate. Rev Soc Bras Med Trop 2005; 38: 213–217.
21. Sassi A, Louzir H, Ben Salah A et al. Leishmanin skin test
lymphoproliferative responses and cytokine production after
symptomatic or asymptomatic Leishmania major infection in Tunisia.
Clin Exp Immunol 1999; 116: 127–132.
22. Reed SG. Diagnosis of leishmaniasis. Clin Dermatol 1996; 24: 471–478.
23. Oliveira RA, Silva Jr GB, Souza CJ et al. Evaluation of renal function in
leprosy: a study of 59 consecutive patients. Nephrol Dial Transplant 2008;
23: 256–262.
24. Veiga JP, Wolff ER, Sampaio RN et al. Renal tubular dysfunction in patients
with mucocutaneous leishmaniasis treated with pentavalent antimonials.
Lancet 1983; 3: 359.
25. Gagliardi AR, Veiga JP, Rosa TT et al. Pentavalent antimonial inhibition of
the osmotic effect of oxytocin on the isolated toad bladder. Braz J Med
Bio Res 1985; 18: 567–571.
Kidney International (2011) 80, 1099–1106 1105
RA de Oliveira et al.: Cutaneous leishmaniasis and tubular dysfunction o r ig ina l a r t i c l e
26. Lima Verde FAA, Lima Verde FA, Daher EF et al. Renal tubular dysfunction
in human visceral leishmaniasis (Kala-azar). Clin Nephrol 2009; 71:
492–500.
27. Kanno K, Sassaki S, Hirata Y et al. Urinary excretion aquaporin-2 in
patients with diabetes insipidus. N Engl J Med 1995; 332: 1540–1545.
28. Wen H, Frokiaer J, Kwon TH et al. Urinary excretion of aquaporin-2 in rat is
mediated by a vasopressin-dependent apical pathway. J Am Soc Nephrol
1999; 10: 1416–1429.
29. Martin PY, Abraham WT, Leiming X et al. Selective V2-receptor
vasopressin antagonism decreases urinary aquaporin-2 excretion in
patients with chronic heart failure. J Am Soc Nephrol 1999; 10: 2165–2170.
30. McKee JA, Kumar S, Ecelbarger CA et al. Detection of Na+ transporter
proteins in urine. J Am Soc Nephrol 2000; 11: 2128–2132.
31. Klingenberg M. Membrane protein oligomeric structure and transport
function. Nature 1981; 290: 449–454.
32. Hewitt SM, Dear J, Star RA. Discovery of protein biomarkers for renal
disease. J Am Soc Nephrol 2004; 15: 1677–1689.
33. Zhou H, Yuen PS, Pisitkun T et al. Collection, storage, preservation and
normalization of human urinary exosomes for biomarker discovery.
Kidney Int 2006; 69: 1471–1476.
34. Gonzales PA, Pisitkun T, Hofferti JD et al. Large-scale proteomics and
phosphoproteomics of urinary exosomes. J Am Soc Nephrol 2009; 20:
363–379.
35. Schuster VL. Function and regulation of collecting duct intercalated cells.
Annu Rev Physiol 1993; 55: 267–288.
36. Petrovic S, Wang Z, Ma L et al. Regulation of the apical Cl-/HCO3
exchanger pendrin in rat cortical collecting duct in metabolic acidosis.
Am J Physiol Renal Physiol 2003; 284: F103–F112.
37. Royaux IE, Wall SM, Karniski LP et al. Pendrin, encoded by the Pendred
syndrome gene, resides in the apical region of renal intercalated cells and
mediates bicarbonate secretion. Proc Natl Acad Sci USA 2001; 98:
4221–4226.
38. Mohebbi N, Mihailova M, Wagner CA. The calcineurin inhibitor FK506
(tacrolimus) is associated with transient metabolic acidosis and altered
expression of renal acid-base transport proteins. Am J Physiol Renal
Physiol 2009; 297: F499–F509.
39. Tryding N, Sterner G, Berg B et al. Subcutaneous and intranasal
administration of 1-deamino-8-d-arginine vasopressin in the assessment
of renal concentration capacity. Nephron 1987; 45: 27–30.
40. Tryding N, Berg B, Ekman S. DDAVP test for renal concentration capacity.
Scand J Urol Nephrol 1988; 22: 141–145.
41. Oster JR. A short duration renal acidification test using calcium chloride.
Nephron 1975; 14: 281–292.
42. Hoffert JD, Nielsen J, Yu MJ et al. Dynamic of aquaporin-2
serine-261 phosphorylation in response to short-term vasopressin
treatment in collecting duct. Am J Physiol Renal Physiol 2007; 292:
F691–F700.
43. Gonzales PA, Pisitkun T, Hoffert JD et al. Large-scale proteomics and
phosphoproteomics of urinary exosomes. J Am Soc Nephrol 2009; 20:
363–379.
1106 Kidney International (2011) 80, 1099–1106
or ig ina l a r t i c l e RA de Oliveira et al.: Cutaneous leishmaniasis and tubular dysfunction
